氨基末端激酶1/3抗體

交叉反應(yīng) Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Rabbit,

產(chǎn)品應(yīng)用 WB=1:500-2000,IHC-P=1:100-500,ICC=1:100,FCM=1μg/Test

保存條件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

氨基末端激酶1/3抗體

JNK1（MAPK8） is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various cell stimuli, and targets specific transcription factors, and thus mediates immediate-early gene expression in response to cell stimuli. The activation of this kinase by tumor-necrosis factor alpha （TNF-alpha） is found to be required for TNF-alpha induced apoptosis. This kinase is also involved in UV radiation induced apoptosis, which is thought to be related to cytochrome c-mediated cell death pathway. Studies of the mouse counterpart of this gene suggested that this kinase play a key role in T cell proliferation, apoptosis and differentiation. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.  JNK1 is activated by threonine and tyrosine phosphorylation by either of two dual specificity kinases, MAP2K4 and MAP2K7.   The JNK pathway is critically involved in diabetes and levels are abnormally elevated in obesity. The cell-permeable JNK inhibitory peptide may have promise as a therapeutic agent for diabetes.

Bioss（博奧森）于2001年在北京成立，是一家擁有自主品牌，集免疫學科研試劑研發(fā)、生產(chǎn)、銷售為一體的國家高新技術(shù)企業(yè)。自成立之初，公司始終秉持“自主研發(fā)、原始創(chuàng)新"的經(jīng)營理念，為生命科學研究提供高質(zhì)量的科研抗體，診斷抗體原料，免疫學輔助試劑，以及CRO服務(wù)。

Bioss Inc.于2010年在美國波士頓設(shè)立了面向全球抗體市場的商務(wù)拓展及國際市場營銷總部，不斷擴展全球銷售體系，主打Bioss國際品牌，向全球科研工作者提供高質(zhì)量的科研抗體產(chǎn)品。迄今為止，Bioss產(chǎn)品已遍布全球多個國家和地區(qū)，并已成為數(shù)家歐美抗體公司的OEM合作伙伴。

二十年的探索和拼搏，為Bioss品牌在免疫學試劑領(lǐng)域奠定了堅實的基礎(chǔ)。我們在美國、中國、德國、日本分別建有現(xiàn)貨庫存，為生命科學研究提供更及時的服務(wù)。